$RVXCF up 14.77% this week and 110% in June Vo
Post# of 98050
Volume still incredibly light, not a single day with even 1 million trading, in fact only a little more than 50K traded hands today.
The penny scalpers are better off playing the pump and dumps, but for those who want something with more long term potential, this one could have staying power, especially if their Phase III clinical trial succeeds in proving that Apabetalone can reduce the risk of Major Adverse Cardiac Events (MACE) by the 30% endpoint target or more.
The trial is projected to be completed around November/December with top line results expected shortly thereafter. Here's the month long chart: